Cover Image
市場調查報告書

Piramal Enterprises Limited的產品平台分析

Piramal Enterprises Limited - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 320925
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Piramal Enterprises Limited的產品平台分析 Piramal Enterprises Limited - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 44 Pages
簡介

Piramal Enterprises Limited是擁有Piramal HealthCare, Piramal Life Sciences, Piramal Capital等部門的多角經營企業,提供醫療資訊管理、生命科學及藥物遞輸系統、財務服務、委託製造等服務。

本報告提供Piramal Enterprises Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Piramal Enterprises Limited的基本資料

  • Piramal Enterprises Limited概要
  • 主要資訊
  • 企業資料

Piramal Enterprises Limited:R&D概要

  • 主要的治療範圍

Piramal Enterprises Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Piramal Enterprises Limited:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Piramal Enterprises Limited:藥物簡介

  • P-276
  • P-1736
  • P-1446
  • P-11187
  • P-2745
  • P-7435
  • P-3971
  • P-7170
  • P-979
  • PM-181104
  • PM-181108
  • Small Molecule for Cancer

Piramal Enterprises Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Piramal Enterprises Limited:最新的開發平台資訊

Piramal Enterprises Limited:開發被休止了的計劃

Piramal Enterprises Limited:開發中止的產品

Piramal Enterprises Limited:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

目錄
Product Code: GMDHC06643CDB

Summary

Global Markets Direct's, 'Piramal Enterprises Limited - Product Pipeline Review - 2014', provides an overview of the Piramal Enterprises Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Piramal Enterprises Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Piramal Enterprises Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Piramal Enterprises Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Piramal Enterprises Limited's pipeline products

Reasons to buy

  • Evaluate Piramal Enterprises Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Piramal Enterprises Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Piramal Enterprises Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Piramal Enterprises Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Piramal Enterprises Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Piramal Enterprises Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Piramal Enterprises Limited Snapshot
    • Piramal Enterprises Limited Overview
    • Key Information
    • Key Facts
  • Piramal Enterprises Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Piramal Enterprises Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Piramal Enterprises Limited - Pipeline Products Glance
    • Piramal Enterprises Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Piramal Enterprises Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Piramal Enterprises Limited - Drug Profiles
    • P-276
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-1736
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-1446
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-11187
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-2745
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-7435
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-3971
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-7170
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-979
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PM-181104
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PM-181108
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Piramal Enterprises Limited - Pipeline Analysis
    • Piramal Enterprises Limited - Pipeline Products by Target
    • Piramal Enterprises Limited - Pipeline Products by Route of Administration
    • Piramal Enterprises Limited - Pipeline Products by Molecule Type
    • Piramal Enterprises Limited - Pipeline Products by Mechanism of Action
  • Piramal Enterprises Limited - Recent Pipeline Updates
  • Piramal Enterprises Limited - Dormant Projects
  • Piramal Enterprises Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • P-1201
      • P-276
      • PM-181110
  • Small Molecule to Inhibit IL-6 for Inflammation
  • Small Molecules for Oncology
  • Piramal Enterprises Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Piramal Enterprises Limited, Key Information
  • Piramal Enterprises Limited, Key Facts
  • Piramal Enterprises Limited - Pipeline by Indication, 2014
  • Piramal Enterprises Limited - Pipeline by Stage of Development, 2014
  • Piramal Enterprises Limited - Monotherapy Products in Pipeline, 2014
  • Piramal Enterprises Limited - Phase II, 2014
  • Piramal Enterprises Limited - Phase I, 2014
  • Piramal Enterprises Limited - Preclinical, 2014
  • Piramal Enterprises Limited - Discovery, 2014
  • Piramal Enterprises Limited - Pipeline by Target, 2014
  • Piramal Enterprises Limited - Pipeline by Route of Administration, 2014
  • Piramal Enterprises Limited - Pipeline by Molecule Type, 2014
  • Piramal Enterprises Limited - Pipeline Products by Mechanism of Action, 2014
  • Piramal Enterprises Limited - Recent Pipeline Updates, 2014
  • Piramal Enterprises Limited - Dormant Developmental Projects,2014
  • Piramal Enterprises Limited - Discontinued Pipeline Products, 2014
  • Piramal Enterprises Limited, Other Locations
  • iramal Enterprises Limited, Subsidiaries

List of Figures

  • Piramal Enterprises Limited - Pipeline by Top 10 Indication, 2014
  • Piramal Enterprises Limited - Pipeline by Stage of Development, 2014
  • Piramal Enterprises Limited - Monotherapy Products in Pipeline, 2014
  • Piramal Enterprises Limited - Pipeline by Top 10 Target, 2014
  • Piramal Enterprises Limited - Pipeline by Top 10 Route of Administration, 2014
  • Piramal Enterprises Limited - Pipeline by Top 10 Molecule Type, 2014
  • Piramal Enterprises Limited - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top